Jinkuk Choi serves as the Scientific Director and Head of the Gene Therapy Performance Group within the Gene Therapy Accelerator Unit (GTxAU) at Biogen, where he plays a pivotal role in shaping the scientific strategy and enhancing the productivity of gene therapy initiatives. With a...
Jinkuk Choi serves as the Scientific Director and Head of the Gene Therapy Performance Group within the Gene Therapy Accelerator Unit (GTxAU) at Biogen, where he plays a pivotal role in shaping the scientific strategy and enhancing the productivity of gene therapy initiatives. With a robust background in drug discovery, Jinkuk has successfully led multiple R&D projects from target validation through to Phase I clinical trials, demonstrating his expertise in small molecule, antisense oligonucleotide (ASO), and gene therapy drug development. His leadership within GTxAU involves not only directing scientific efforts but also fostering strategic collaborations that align with Biogen's overarching goals in advancing innovative therapies for neurological diseases.
Jinkuk's deep knowledge in molecular and cellular biology, coupled with his proficiency in pharmacology and translational medicine, enables him to navigate the complexities of gene therapy research effectively. He is adept at integrating systems biology approaches to enhance the understanding of therapeutic mechanisms and optimize drug design. His commitment to improving the GTx portfolio is evident in his ability to streamline project management processes and drive cross-functional collaboration, ensuring that scientific advancements translate into tangible clinical outcomes.
As a member of the leadership team, Jinkuk is instrumental in influencing the strategic direction of the GTxAU, leveraging his extensive experience to mentor emerging scientists and cultivate a culture of innovation. His exceptional presentation skills and ability to communicate complex scientific concepts clearly make him a sought-after collaborator within the pharmaceutical industry, further solidifying his reputation as a leader in the field of gene therapy.
